Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care

BMC Cancer

Table 4 Patterns of disease progression^a

	BRAF n = 87 (100.0)	NRAS n = 53 (100.0)	Wild type n = 72 (100.0)	total n = 212^a (100.0)	p-value
Local relapse
no	86 (98.9)	49 (92.5)	71 (98.6)	206 (97.2)	0.057
yes	1 (1.2)	4 (7.6)	1 (1.4)	6 (2.8)	0.057
Relapse of nodal disease (loco-regional)
no	56 (64.4)	21 (39.6)	43 (59.7)	120 (56.6)	0.013*
yes	31 (35.6)	32 (60.4)	29 (40.3)	92 (43.4)	0.013*
Distant metastases^b
no	18 (21.2)	6 (12.0)	23 (33.3)	47 (23.0)	0.021
yes	67 (78.8)	44 (88.0)	46 (66.7)	157 (77.0)	0.021

The frequency and types of disease progression are displayed according to the genotype. Patients were allowed to have more than one progression type. Statistical analyses were performed with the Chi-square test; the significance level was adjusted with the Bonferroni correction with p < 0.017 considered significant (*). ^a n = 4 patients had disease progression, but the specific progression type was unknown; ^bpatients initially presenting in stage M1 (IV) were excluded (n = 8)

ISSN: 1471-2407